Ditchcarbon
  • Contact
  1. Organizations
  2. Millennium Pharmaceuticals, Inc.
Public Profile
Pharmaceutical Preparation Manufacturing
US
updated 23 days ago

Millennium Pharmaceuticals, Inc. Sustainability Profile

Company website

Millennium Pharmaceuticals, Inc., a subsidiary of Takeda Pharmaceutical Company, is a prominent player in the biotechnology industry, headquartered in the United States. Founded in 1993, the company has made significant strides in oncology, focusing on innovative therapies for cancer treatment. With a strong presence in North America and Europe, Millennium is renowned for its commitment to advancing cancer care through cutting-edge research and development. The company’s flagship products, including Velcade and Ninlaro, are distinguished by their unique mechanisms of action, offering new hope to patients with multiple myeloma and other malignancies. Millennium's dedication to scientific excellence has positioned it as a leader in the oncology market, with numerous accolades recognising its contributions to cancer therapeutics. Through its ongoing efforts, Millennium Pharmaceuticals continues to shape the future of cancer treatment, striving to improve patient outcomes worldwide.

DitchCarbon Score

How does Millennium Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

72

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

31

Industry Benchmark

Millennium Pharmaceuticals, Inc.'s score of 72 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.

82%

Let us know if this data was useful to you

Millennium Pharmaceuticals, Inc.'s reported carbon emissions

Inherited from Takeda Pharmaceutical Company Limited

Millennium Pharmaceuticals, Inc., headquartered in the US, currently does not report specific carbon emissions data, as no figures are available. However, the company is a current subsidiary of Takeda Pharmaceutical Company Limited, which influences its climate commitments and initiatives. Millennium Pharmaceuticals inherits its climate-related targets and performance metrics from Takeda Pharmaceutical Company Limited. This includes commitments to the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP), both of which are aimed at reducing greenhouse gas emissions across their operations. The specific reduction targets and achievements of Takeda, which cascade down to Millennium, are not detailed in the available data. As part of its corporate family, Millennium Pharmaceuticals aligns with Takeda's broader sustainability goals, which focus on reducing emissions across all scopes, including Scope 1, 2, and 3. While specific numbers are not provided, the overarching commitment to climate action reflects a dedication to addressing environmental impacts within the pharmaceutical industry. In summary, while Millennium Pharmaceuticals, Inc. does not have specific emissions data or reduction targets available, it is guided by the climate initiatives and performance metrics of its parent company, Takeda Pharmaceutical Company Limited.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

201520162020202120222023
Scope 1
96,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
Scope 2
161,000,000
000,000,000
000,000,000
000,000,000
000,000,000
00,000,000
Scope 3
226,000,000
-
0,000,000,000
0,000,000,000
0,000,000,000
0,000,000,000

How Carbon Intensive is Millennium Pharmaceuticals, Inc.'s Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Millennium Pharmaceuticals, Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Millennium Pharmaceuticals, Inc.'s Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Millennium Pharmaceuticals, Inc. is in US, which has a low grid carbon intensity relative to other regions.

Millennium Pharmaceuticals, Inc.'s Scope 3 Categories Breakdown

Millennium Pharmaceuticals, Inc.'s Scope 3 emissions, which decreased by 23% last year and increased significantly since 2015, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 68% of Scope 3 emissions.

Top Scope 3 Categories

2023
Purchased Goods and Services
68%
Upstream Transportation & Distribution
9%
End-of-Life Treatment of Sold Products
7%
Capital Goods
6%
Fuel and Energy Related Activities
4%
Business Travel
3%
Employee Commuting
2%
Investments
1%
Waste Generated in Operations
<1%
Processing of Sold Products
<1%

Millennium Pharmaceuticals, Inc.'s Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Millennium Pharmaceuticals, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Millennium Pharmaceuticals, Inc.'s Emissions with Industry Peers

Eisai

JP
•
Pharmaceutical Preparation Manufacturing
Updated 14 days ago

Genmab

DK
•
Pharmaceutical Preparation Manufacturing
Updated 9 days ago

Celgene Corporation

US
•
Pharmaceutical Preparation Manufacturing
Updated 20 days ago

Janssen Biotech, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated about 2 months ago

Amgen

US
•
Pharmaceutical Preparation Manufacturing
Updated 7 days ago

Johnson And Johnson

US
•
Pharmaceutical Preparation Manufacturing
Updated about 8 hours ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251030.3
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy